文献速递创伤骨科关节外科

部分Vancouver B2型股骨假体周围骨折可安全采用内固定治疗

Selected Vancouver B2 periprosthetic femoral fractures around cemented polished femoral components can be safely treated with osteosynthesis.
PubMed 文献 · Bone Joint J · 2021-01-01

本研究回顾性比较了Vancouver B1型内固定、B2型内固定及B2型翻修关节置换的假体生存率、并发症、再入院和死亡率。B2型内固定基于特定影像学(抛光股骨柄、骨水泥界面完整)和临床标准(低需求患者)选择。结果显示三组24个月假体生存率无显著差异,B2型内固定组与B1型内固定及B2型翻修组相当。

要点

  • B2型内固定24个月假体生存率90%,与B1型内固定95.4%及B2型翻修85.8%无显著差异(p=0.296)。
  • 所有手术失败均发生在术后24个月内。
  • 低需求老年患者、骨水泥抛光股骨柄且骨水泥界面完整的B2型骨折可安全内固定。

核心结论

  • Vancouver B2型股骨假体周围骨折内固定后的假体生存率与B1型内固定和B2型翻修关节置换相似。
  • 低需求老年患者,若骨折围绕固定良好的骨水泥抛光股骨柄且骨水泥界面完整,可安全采用内固定治疗。

研究设计与样本

  • 回顾性研究,共纳入112例股骨假体周围骨折,其中47例(42%)B1型和27例(24%)B2型接受内固定,38例(34%)B2型接受翻修关节置换。
  • B2型内固定的决策基于特定影像学标准(抛光股骨组件、骨水泥界面完整)和临床标准(低需求患者)。
  • 中位随访36.4个月(24至60个月),采用Kaplan-Meier法估计假体生存率和死亡率。

主要发现

  • 共检测到9例(8.01%)手术失败,所有失败均发生在术后24个月内。
  • 24个月假体生存率:B1型内固定组95.4%(95%CI 89.13至100),B2型单纯内固定组90%(95%CI 76.86至100),B2型翻修THA组85.8%(95%CI 74.24至97.36),组间无显著差异(p=0.296)。
  • 再入院和主要不良事件(包括死亡)总体较高,但组间相似(p>0.05)。
  • 两年患者生存率:B1组87.1%(95%CI 77.49至95.76),B2内固定组66.7%(95%CI 48.86至84.53),B2翻修组84.2%(95%CI 72.63至95.76),组间无显著差异(p=0.102)。

关键数值与推荐

  • B2型内固定适用于满足以下条件的患者:低需求、老年、股骨组件为骨水泥抛光柄、骨水泥界面完整。

临床怎么用

  • 对于低需求老年患者,若Vancouver B2型骨折围绕固定良好的骨水泥抛光股骨柄且骨水泥界面完整,可选择内固定而非翻修关节置换。

局限性

  • 回顾性研究设计。
  • 样本量有限(共112例,B2内固定组仅27例)。
  • 中位随访36.4个月,可能不足以评估长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: We aimed to compare the implant survival, complications, readmissions, and mortality of Vancouver B2 periprosthetic femoral fractures (PFFs) treated with internal fixation with that of B1 PFFs treated with internal fixation and B2 fractures treated with revision arthroplasty. METHODS: We retrospectively reviewed the data of 112 PFFs, of which 47 (42%) B1 and 27 (24%) B2 PFFs were treated with internal fixation, whereas 38 (34%) B2 fractures underwent revision arthroplasty. Decision to perform internal fixation for B2 PFFs was based on specific radiological (polished femoral components, intact bone-cement interface) and clinical criteria (low-demand patient). Median follow-up was 36.4 months (24 to 60). Implant survival and mortality over time were estimated with the Kaplan-Meier method. Adverse events (measured with a modified Dindo-Clavien classification) and 90-day readmissions were additionally compared between groups. RESULTS: In all, nine (8.01%) surgical failures were detected. All failures occurred within the first 24 months following surgery. The 24-month implant survival was 95.4% (95% confidence interval (CI) 89.13 to 100) for B1 fractures treated with internal fixation, 90% (95% CI 76.86 to 100) for B2 PFFs treated with osteosynthesis-only, and 85.8% (95% CI 74.24 to 97.36) for B2 fractures treated with revision THA, without significant differences between groups (p = 0.296). Readmissions and major adverse events including mortality were overall high, but similar between groups (p > 0.05). The two-year patient survival rate was 87.1% (95% CI 77.49 to 95.76), 66.7% (95% CI 48.86 to 84.53), and 84.2% (95% CI 72.63 to 95.76), for the B1 group, B2 osteosynthesis group, and B2 revision group, respectively (p = 0.102). CONCLUSION: Implant survival in Vancouver B2 PFFs treated with internal fixation was similar to that of B1 fractures treated with the same method and to B2 PFFs treated with revision arthroplasty. Low-demand, elderly patients with B2 fractures around well-cemented polished femoral components with an intact bone-cement interface can be safely treated with internal fixation. Cite this article: Bone Joint J 2021;103-B(7):1222-1230.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Slullitel PA, Garcia-Barreiro GG, Oñativia JI, et al. Selected Vancouver B2 periprosthetic femoral fractures around cemented polished femoral components can be safely treated with osteosynthesis. Bone Joint J. 2021. PMID: 34192924. doi:10.1302/0301-620X.103B7.BJJ-2020-1809.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。